03 October 2016
IntegraGen will present an update on the ICE Project (Interpretation of Clinical Exome) during the MEDICEN PARIS REGION meeting being held on Wednesday, October 5, 2016 at the headquarters of Bpifrance. This meeting will be attended by the organization’s members, partners and (…) »
04 September 2016
Results from a new analysis of the predictive miR 31-3p biomarker for metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 clinical trial will be featured as an oral presentation during a proffered session at the upcoming 2016 European Society of Medical Oncology (ESMO) Congress. Professor Pierre Laurent-Puig, (…) »
07 July 2016
IntegraGen has announced its sales for the first half 2016. The company reported strong growth for its clinical research and microbiology genomics businesses and stability in its genomic services business for research activities with a significant increase in orders across all genomic activities.
29 June 2016
The Greater Paris University Hospitals (AP-HP) and IntegraGen announced today an agreement to develop a high-throughput sequencing platform (exome and whole genome) to be utilized for research projects and clinical research initiatives. This three-year research partnership aligns with a major objective of AH-HP’s 2015-2019 Strategic Plan related to (…) »
10 June 2016
06 June 2016
IntegraGen presented positive clinical results on its miR-31-3p biomarker during the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago. The data presented demonstrates that IntegraGen’s proprietary miR-31-3p biomarker is predictive for both survival and treatment response in patients receiving anti-EGFR therapy.
(…) »
19 May 2016
The results from an analysis of miR 31-3p expression for metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 trial will be presented at ASCO 2016 in Chicago during a poster discussion session being held from 1:15 p.m. to 2:30 p.m. on Saturday, June 4, 2016 (Hall D). (…) »
08 April 2016
IntegraGen today announced its financial results for the year ended 31 December 2015.
The financial statements were reviewed by the Company’s Board of Directors during a meeting held on April 7, 2016.17 March 2016
16 February 2016
IntegraGen’s oncology Scientific Advisory Board (SAB) recently met at the venue of the 2016 American Society of Oncology’s (ASCO) Gastrointestinal Cancers Symposium in San Francisco to review the results from the latest clinical study exploring the predictivity of miR-31-3p on the efficacy of anti-EGFR therapy in all-RAS wild-type metastatic colorectal cancer (…) »
